MHC class I molecules are expressed on the surface of all nucleated cells and play a significant role in graft rejection. B2m, the non-polymorphic constituent of the MHC class I molecule, is crucial to the structural integrity of the MHC class I. Targeting B2m using gene editing technologies to generate cells with minimal or no surface MHC class I expression is a promising strategy for addressing graft rejection. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is among the most effective approaches to editing genes, in vitro and in vivo, in a wide range of cell lines and species. However, delivery methods to transfer the CRISPR/Cas9 system to the cells can bring up challenges. In this study, we have deployed FolicPolySpermine nanoparticles based on spermine, polyethylene glycol, and folic acid for the transfection of two gRNAs targeting B2m and Cas9 into the HEK293T cell line. These nanoparticles were effectively transferred to the HEK293T cells, and we validated the expression and functionality of the CRISPR/Cas9 system within the cells. Moreover, we compared the efficiency of lipofectamine 2000 and FolicPolySpermine as delivery systems. FolicPolySpermine nanoparticle, as a biocompatible, safe, and efficient strategy, is useful in the transfection of CRISPR plasmids with high efficacy and precision into the target cells. Additionally, our study demonstrated that the use of dual gRNAs is a suitable approach for directly targeting and inducing predicted deletions at specific loci, which can be utilized for gene knockout purposes. All in all, our findings highlight the potential of FolicPolySpermine as a promising gene delivery method for the CRISPR/Cas9 system.
扫码关注我们
求助内容:
应助结果提醒方式:
